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Cancer Therapy: Preclinical
The mTOR Kinase Inhibitors, CC214-1 and CC214-2,
Preferentially Block the Growth of EGFRvIII-Activated
Glioblastomas
Beatrice Gini1,3, Ciro Zanca1, Deliang Guo13, Tomoo Matsutani1, Kenta Masui1, Shiro Ikegami1, Huijun Yang1,
David Nathanson1, Genaro R. Villa1,10,11, David Shackelford1, Shaojun Zhu1, Kazuhiro Tanaka1, Ivan Babic1,
David Akhavan1, Kelly Lin1, Alvaro Assuncao1, Yuchao Gu1,10, Bruno Bonetti14, Deborah S. Mortensen4,
Shuichan Xu4, Heather K. Raymon4, Webster K. Cavenee1,2,3, Frank B. Furnari1,2,3, C. David James5, Guido
Kroemer15,16,17,18,19, James R. Heath6, Kristen Hege12, Rajesh Chopra12, Timothy F. Cloughesy7,8,9, and Paul
S. Mischel1,2,3
Abstract
Purpose: mTOR pathway hyperactivation occurs in approximately 90% of glioblastomas, but the
allosteric mTOR inhibitor rapamycin has failed in the clinic. Here, we examine the efficacy of the newly
discovered ATP-competitive mTOR kinase inhibitors CC214-1 and CC214-2 in glioblastoma, identifying
molecular determinants of response andmechanisms of resistance, and develop a pharmacologic strategy to
overcome it.
Experimental Design: We conducted in vitro and in vivo studies in glioblastoma cell lines and an
intracranial model to: determine the potential efficacy of the recently reported mTOR kinase inhibitors
CC214-1 (in vitro use) and CC214-2 (in vivo use) at inhibiting rapamycin-resistant signaling and blocking
glioblastoma growth and a novel single-cell technology—DNA Encoded Antibody Libraries—was used to
identify mechanisms of resistance.
Results: Here, we show that CC214-1 and CC214-2 suppress rapamycin-resistant mTORC1 signaling,
blockmTORC2 signaling, and significantly inhibit the growth of glioblastomas in vitro and in vivo. EGFRvIII
expression and PTEN loss enhance sensitivity to CC214 compounds, consistent with enhanced efficacy in
strongly mTOR-activated tumors. Importantly, CC214 compounds potently induce autophagy, preventing
tumor cell death.Genetic or pharmacologic inhibitionof autophagy greatly sensitizes glioblastoma cells and
orthotopic xenografts to CC214-1- and CC214-2–induced cell death.
Conclusions: These results identify CC214-1 and CC214-2 as potentially efficacious mTOR kinase
inhibitors in glioblastoma, and suggest a strategy for identifying patients most likely to benefit frommTOR
inhibition. In addition, this study also shows a central role for autophagy in preventing mTOR-kinase
inhibitor-mediated tumor cell death, and suggests a pharmacologic strategy for overcoming it. Clin Cancer
Res; 19(20); 5722–32. 2013 AACR.
Introduction
Glioblastoma is the most common malignant primary
brain cancer in adults and one of the most lethal of all
cancers (1). Phosphoinositide 3-kinase (PI3K) signaling is
hyperactivated in approximately90%ofglioblastomas, com-
monly in association with EGF receptor (EGFR) amplifica-
tion and mutation, and loss of the PTEN tumor suppressor
protein (2, 3). ThemTOR kinase—which links growth factor
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receptor signaling through PI3K with protein translation,
proliferation, and survival—is, therefore, frequently hyper-
activated in many cancer types, including the majority of
glioblastomas (4, 5). mTOR functions through two well-
described multiprotein complexes: mTORC1, which pro-
motesmanyof its cellular activities throughphosphorylation
of S6 kinase and 4E-BP1, and mTORC2, which phosphor-
ylates Akt to maximize its activity (5). Despite the central
importanceofmTORsignaling in glioblastoma, the allosteric
mTORC1 inhibitor rapamycin has been shown to be inef-
fective inpatientswith glioblastoma(6, 7). Recentwork from
our group shows that this is mediated, at least in part, by
failure to suppress mTORC2 signaling (6). Further, rapamy-
cin has also been shown to be ineffective at durably suppres-
sing 4E-BP1 phosphorylation in certain cellular contexts,
suggesting that rapamycin-resistant mTORC1 signaling may
also underlie clinical failure (8, 9).
ATP-competitive mTOR kinase inhibitors, which could
potentially suppress rapamycin-resistant mTORC1 and
mTORC2 signaling, have the potential to improve the
treatment of patients with glioblastoma. However to date,
their efficacy, molecular determinants of sensitivity, and
potential mediators of resistance are not understood. Here,
we conduct a series of in vitro and in vivo studies in glio-
blastoma cell lines to determine the potential efficacy of the
recently reportedmTOR kinase inhibitors CC214-1 (in vitro
use) and CC214-2 (in vivo use) at inhibiting rapamycin-
resistant signaling and blocking glioblastoma growth (10).
We identify molecular determinants of sensitivity, and
show that autophagy plays a central role in preventing
CC214-mediated cell death, which can be reversed by
genetic or pharmacologic inhibition of autophagy. These
results identify CC214-1 and CC214-2 as potentially effec-
tive agents, particularly in combination with lysosomotro-
pic, autophagy-inhibitory compounds.
Materials and Methods
Cell lines and reagents
The U87, U87EGFRvIII, U87EGFR, and U87EGFRvIII/-
PTEN cells were obtained as previously described (5); U251
and LN229 were cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Cellgro) supplemented with 10% FBS
(vol/vol, Omega Scientific) and 100 U/mL penicillin and
streptomycin (Gibco); the U373 Tet OFF systemwas kindly
provided by the Webster Cavenee group (Ludwig Inst., San
Diego, CA); the LN229 Tet ON cell lines were grown as
described in the work by Guo and colleagues (11). GBM39
primary neurospheres were provided by Prof. David James
(University of California at San Francisco, San Francisco,
CA).All cell lineswere cultured in ahumidified5%CO2(vol/
vol) incubator, at 37C. CC214-1 and CC214-2 were pro-
vided by Celgene Corporation (San Diego, CA). The devel-
opment of the series that led to CC214 compounds (12) and
its structure (10) have been described previously. P-Akt
Ser473, P-Akt Thr308, P-NDRG1 Thr346, P-S6 Ser235/
236, S6, cleaved PARP, P-4E-BP1 Thr37-46, 4E-BP1, eIF4E,
LC3B, Atg-5, and Atg-5/12 antibodies were purchased from
Cell Signaling Technologies. P-EGFR Tyr1086 and P-PRAS40
Thr246 were from Invitrogen. EGFRvIII was made by Dako.
Actin, p62, and PTEN antibodies were purchased, respective-
ly, from Novus Biologicals, Progen Biotechnik, and Cascade
BioScience. Chloroquine was from Sigma.
Immunoblotting
Western blot analysis was conducted using a 10 to 50 mg
range of total protein lysates. Lysates were obtained from
cultured cells or snap-frozen tissues using radioimmuno-
precipitation assay (RIPA) buffer (Boston BioProducts) and
protease plus phosphatase inhibitor cocktail (Thermo Sci-
entific). Monodimensional electrophoresis was applied in
4% to 12% gradient gels NuPAGE Bis–Tris Mini Gel (Invi-
trogen); 10% or 15% acrylamide (vol/vol; National Diag-
nostics) gels were made and used to improve middle- and
low-molecular weight (MW) protein separation. Proteins
have then been transferred on nitrocellulose membranes
(GEHealthcare), using a BioRad transfer chamber, applying
110 Volts for 1 hour. Membranes were subsequently
blocked in Tris-buffered saline containing 0.1% Tween20
(vol/vol) and 5% BSA (g/mL; Fischer Scientific) for 1 hour.
Primary antibody incubations were conducted overnight, at
4C. Incubation with secondary horseradish peroxidase
(HRP)-conjugated antibodies was done at room tempera-
ture (RT) for 1 hour. Detection of the immunoreactivities
was obtained with Super Signal West Pico Chemilumines-
cent Substrate or West Femto Trial kit (Thermo Scientific).
Scanned films or digitalized images acquired by Chemidoc
(BioRad), Image Lab 4.0.1, were quantified using Image J
software (NIH).
Cell proliferation
Water Soluble Tetrazolium (WST) assay was conducted
with the Cell Proliferation Assay Kit (Chemicon). Specifi-
cally, cells were seeded at a density of 1 103 cells eachwell
in 1% FBS DMEM (vol/vol), then a first reading after
Translational Relevance
Despite the compelling nature of mTOR as a drug
target in glioblastoma, the allosteric inhibitor rapamycin
has failed to show benefit for patients of glioblastoma,
potentially because of a failure to fully suppress mTOR
signaling. Here, we show that the newly described ATP-
competitive mTOR kinase inhibitors CC214-1 and
CC214-2 suppress rapamycin-resistant mTORC1 signal-
ing, block mTORC2 signaling, and significantly inhibit
the growth of glioblastomas in vitro and in vivo; in
addition, we identify EGFRvIII and PTEN loss as molec-
ular determinants of response. We further show autop-
hagy as a resistancemechanism, which can be overcome
with the addition of chloroquine. Taken together, this
study identifies potentially efficacious newmTORkinase
inhibitors, couples it to a strategy to direct it to patients
most likely to benefit, and suggests a combinatorial
pharmacologic approach to suppress autophagy-depen-
dent drug resistance.
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adhesion was done; thereafter, drug treatment was started
and continued for up to 4 days. On each day of reading,
plates were incubated for 2 hours with tetrazolium salt
WST 1 [2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-
phenyl)-2H-tetrazolium, monosodium salt] (Chemicon) in
the incubator. The absorbance was measured with a micro-
plate reader (BioRad) at 420 to 480 nm.
Viability tests
Fifteen thousand glioblastoma cells were seeded in 12-
well plates and treated, after one night, withCC214-1 at 0.1,
1, 2, 5, and 10mmol/L. Chloroquine 10mmol/Lwas used for
combinatory treatment. Cell viability was evaluated after 3
days of treatment, and assessed by trypan blue exclusion
(Invitrogen).
Flow cytometry analysis: Annexin V, PI
Viability was assessed in glioblastoma cell lines
with the Annexin V, PI kit (BD), according to the manufac-
turer’s instructions, after 72 hours of CC214-1 (2 mmol/L)
treatment.
In vivo experiments
Flank xenografts. U87EGFRvIII xenografts models
were obtained in full compliance with the University of
California Los Angeles (UCLA)-Division of Laboratory
Animal Medicine (DLAM) regulation and after approval
by the Chancellor’s Animal Research Committee of
UCLA. In particular, U87-EGFRvIII cells were implanted
subcutaneously in immunocompromised nonobese dia-
betic severe-combined immunodeficient (NOD/SCID)-g
null mice. Cells were cultured, trypsinized, and resus-
pended in PBS (Cellgro) plus Matrigel (BD Biosciences),
as a 1:1 solution, at 6  106 cells/mL density. Tumor sizes
were monitored daily using automated caliper. CC214-2
treatment, 50 mg/kg, was done by oral gavage, once every
day in a suspension containing 0.5% carboxymethylcel-
lulose (g/mL, Sigma), 0.25% Tween-80 (vol/vol; Sigma)
in nanopure water. Mice were euthanized when tumors
reached 15 mm diameter.
Orthotopic xenografts. U87EGFRvIII-TurboFP635 ortho-
topic xenografts models were obtained in full compliance
with the University of California San Diego (UCSD)-Insti-
tutional Animal Core and Use Committee (IACUC).
Plasmid and cells. TurboFP635 fluorescent protein was
used to tag U87EGFRvIII cells that were injected intracra-
nially. Briefly, the lentiviral LV plasmid (13) was digested
with NheI and XhoI. The same restriction enzymes were
used to subclone the far-red fluorescent TurboFP635 pro-
tein sequence in the vector (Evrogen JSC). The lentiviruswas
obtained by transient transfection of 293T cells. The
U87EGFRvIII cells were then infectedwith the virus carrying
the sequence for the far-red protein TurboFP635 and sub-
jected to two cycles of fluorescence-activated cell sorting
(FACS) to sort and enrich the most fluorescent 5% cell
population in each cycle.
Intracranial injection procedure. A total of 1  105
U87EGFRvIII cells, tagged with the far-red protein Tur-
boFP635 in a 5 mL volume, were injected intracranially
into 4-week-old athymic nude mice using a stereotactic
system according to the protocol described by Lee and
colleagues (14). In vivo tumors were measured using near-
infrared quantitative fluorescence imaging by fluores-
cence molecular tomography (FMT; FMT 2500, PerkinEl-
mer). Tumor fluorescence emission, at 635 nm, was
collected on the first day of treatment and on the day
the animals were sacrificed. CC214-2 treatment, at 100
mg/kg, was done by oral gavage, once every 2 days in
a suspension containing 0.5% carboxymethylcellulose
(g/mL; Sigma), 0.25% Tween-80 (vol/vol, Sigma) in
nanopure water. Chloroquine, 30 mg/kg in nanopure
water, was administered intraperitoneally, once every 2
days. Mice were euthanized in accordance with the UCSD
Institutional Guidelines for Animal Welfare and Experi-
mental Conduct. Survival until the onset of neurologic
sequelae in the vehicle mice was considered to determine
the time of sacrifice.
Immunohistochemistry and immunofluorescence
Paraffin-embedded U87EGFRvIII xenografts blocks were
sectioned at the UCLA Pathology Histology and Tissue
Core Facility and at the UCSD Histology and Immunohis-
tochemistry Shared Resource. Immunohistochemistry
(IHC) was conducted as described by Mellinghoff and
colleagues (15). Three images per IHC slide were captured
using a DP 26 camera mounted on an Olympus BX43
microscope at 40 magnification. Quantitative analysis of
the IHC-stained slides was conducted with the image-ana-
lyzing software Microsuite Five (Olympus). Immunofluo-
rescence staining was done as previously described in Gini
and colleagues (16).
Cap-binding proteins assay
U87EGFRvIII cells were treatedwithCC214-1 (2mmol/L)
or rapamycin (5 nmol/L) for 24 hours. Five hundredmicro-
gram of protein lysates from control and treated cells,
obtained as described in the "Immunoblotting," were incu-
bated with 7-Methyl GTP Sepharose (GE Healthcare) for 4
hours at 4C, on a rotating shaker. Resin was then centri-
fuged for 90 seconds at 1,800 rpm and pellet-washed twice
with RIPA buffer. Resin was further incubated for 5minutes
at 99C with loading buffer 2. After centrifugation, cap-
binding proteins were collected in the supernatant and
analyzed by immunoblotting.
Capture of EGFR, EGFRvIII-positive cells by DNA-
encoded antibody library
Capture of EGFR, EGFRvIII-positive cells from GBM39
neurospheres has been conducted by DNA encoded anti-
body library (DEAL) as described in Bailey and colleagues
(17). Briefly, DEAL array (CalTech) was blocked with 1%
BSA solution (g/mL) for 30 minutes, washed in PBS and
deionized water, and then incubated with oligo-cetuximab
(Bristol–Myers) conjugate for 30 minutes, at 37C. The
array was washed with 0.1% BSA in PBS (g/mL), and a
single-cell suspension of GBM39 cells was applied on it for
Gini et al.
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40minutes, in ice. After washing, the array of cells was used
for immunofluorescence assay.
Short hairpin RNA assay
Escherichia coli carrying sh-Atg-5 pLKO.1 plasmids (Sig-
ma) were expanded in LB medium (Fisher Scientific)
and then the plasmids were extracted using MidiPrep kit
(Qiagen). For lentiviral production, 293T cells were trans-
fected with sh-Atg-5 pLKO.1 or sh-scramble pLKO.1,
together with packaging, envelope plasmids, and polybrene
(Sigma). Viral harvesting was achieved after 2 days from
transfection, in high BSA growth medium. Sixty-thousand
U87EGFRvIII cells were seeded in 6-cm plates and infected
over night with lentivirus carrying sh-Atg5 or sh-scramble
Figure 1. A, CC214-1 induces potent mTORC1/mTORC2 inhibition and tumor growth reduction in glioblastoma cell lines in vitro. Immunoblotting analysis of
mTORC1/2 effectors activities, after 8 hours of treatment with CC214-1 or rapamycin at increasing concentrations, in U87EGFRvIII, LN229, and
U251 glioblastoma cell lines. B, cellular proliferation in three glioblastoma cell lines as assessed by trypan blue exclusion cell count and normalized to
dimethyl sulfoxide (DMSO) control. U87EGFRvIII proved to be the most sensitive glioblastoma cell line assessed, with IC50 in the 0.5 mmol/L range
(B). C, inhibition of cap-dependent translation by CC214-1 (2 mmol/L) or rapamycin (5 nmol/L), was assessed by the level of 4E-BP1 bound to the 50-cap in
U87EGFRvIII cell lysates after 24 hours of treatment. D, WST proliferation experiment in U87EGFRvIII cells comparing DMSO, CC214-1 (2 mmol/L) and
rapamycin (5 nmol/L) treatments. (P-S6, P-4E-BP1 have been selected as themTORC1biomarker's activity; P-Akt-S473, P-PRAS40, and P-NDRG1were the
selected mTORC2 effectors). , P < 0.05; , P < 0.0001 (Student t test). Data represent average of three independent experiments.
mTOR Kinase Inhibition in Glioblastoma
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plasmids. Selection of sh-positive cells was achieved
after 10 days of growth in medium containing puromycin
(2 mg/mL; Sigma).
Crystal violet analysis
Twenty thousand U87EGFRvIII sh-scramble and
U87EGFRvIII sh-Atg5 cells were seeded in six-well plates
under puromycin selection. After 3 days of incubation in
CC214-1, 2 mmol/L, cells were shortly air dried, fixed for 5
minutes in ParaFormAldehyde (PFA) 4% (vol/vol;
Santa Cruz Biotechnology) and stained in 0.05% crystal
violet (g/mL; Sigma) solution for 30 minutes. Plates were
then washed twice with tap water and air dried for 2
minutes. Pictures of the plates were taken using a Nikon
Eclipse TS100 scope equipped Canon S51S camera.
Results
CC214-1 inhibits rapamycin-resistant mTORC1 and
mTORC2 signaling, limits protein translation, and
blocks glioblastoma cell proliferation
We examined the biochemical and antiproliferative effect
of CC214-1 on a panel of glioblastoma cell lines (Fig. 1A and
B; Supplementary Fig. S1). CC214-1 dose-dependently
inhibited mTORC1 signaling in all glioblastoma cell lines
tested, potently suppressing rapamycin-resistant 4E-BP1 and
mTORC2 signaling, as shown by effects on 4E-BP1 (Thr 37-
46), andAkt (Ser 473), PRAS40 (Thr 246), andNDRG-1 (Thr
346) phosphorylation, respectively (Fig. 1A; Supplementary
Fig. S1). This was confirmed even in the presence of a
rapamycin concentration 10 times higher (50 nmol/L) than
theminimal effectivedose (5nmol/L) that inhibitsmTORC1
(Fig. 1A). Consistentwith the enhanced inhibitionof 4E-BP1
phosphorylation, CC214-1 showed markedly suppressed
m7G cap-dependent translation relative to rapamycin, indi-
cating that the dual mTOR kinase inhibitor was significantly
more efficacious atblockingmTOR-dependentprotein trans-
lation (Fig. 1C). Further, CC214-1 was significantly more
effective than rapamycin at blocking glioblastoma cell pro-
liferation in culture (Fig. 1D). We have recently shown that
ATP-competitive mTOR kinase inhibitors synergize with
rapalogs (18). Consistent with these findings, CC214-1
synergized with rapamycin, inhibiting mTORC1 signaling
and tumor cell proliferation at subtherapeutic doses of each
compound (Supplementary Fig. S2A).
EGFRvIII expression and PTEN loss sensitize tumor
cells to CC214-1
To test the hypothesis that EGFR activation promotes
sensitivity to CC214-1, we examined the impact of EGFRvIII
or EGF-stimulation of wild-type EGFR, in isogenic gliobl-
astoma cell lines. Biochemical analyses confirmed that
CC214-1 successfully inhibitedmTORC1-dependent4E-BP1
and S6 phosphorylation in EGFRvIII-expressing glioblasto-
ma cells (Fig. 2A–C; Supplementary Figs. S2B and S3A), as
well as blocked EGF-induced 4E-BP1 and S6 phosphoryla-
tion in glioblastoma cells overexpressing wild-type EGFR
(Supplementary Fig. S3B). Further, CC214-1 showed super-
ior inhibition of P-Akt (Ser 473), P-S6 (Ser 235-236), and P-
Figure 2. A, EGFRvIII expression
and PTEN loss sensitize
glioblastoma cells to CC214-1–
dependent inhibition of
proliferation. CC214-1 efﬁcacy has
been evaluated in a panel of
isogenic U87 cell lines differentially
expressing EGFRvIII and PTEN.
B, reduction of mTORC1 and
mTORC2 biomarkers followed
CC214-1 treatment (2 mmol/L) was
observed in all of the three cell lines
by Western blot. C, cellular
proliferation in three isogenic U87
cell lines as assessed by trypan
blue exclusion cell count after
treatment with CC214-1 and
normalization to DMSO control.
The EGFRvIII-positive and
PTEN-negative U87 cell line
(U87EGFRvIII) proved to be the
most sensitive, when compared
with EGFRvIII-negative, PTEN-
negative cells (U87), or EGFRvIII-
positive, PTEN-positive cells
(U87EGFRvIIIPTEN) (C). Data
represent average of three
independent experiments.
, P < 0.05 (Student t test).
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4E-BP1 (Thr 37-46) phosphorylation relative to any of the
other EGFR, PI3K, or mTOR inhibitors tested (Supplemen-
tary Fig. S3B). Importantly, EGFRvIII sensitized U87 glio-
blastoma cells toCC214-1–mediated growth inhibition (Fig.
2C), an observation that was validated in another isogenic
cell system, U373 glioblastoma cells, in which EGFRvIII was
under the control of a tetracycline-regulated promoter (Sup-
plementary Fig. S4A). PTEN reconstitution rendered glio-
blastoma cells less sensitive, despite similar levels of pathway
inhibition (Fig. 2C).Weusedanovel technology,DEAL(19),
to capture and analyze individual EGFRvIII expressing tumor
cells from the heterogeneous patient-derived glioblastoma
model, GBM39, in which individual tumor cells varied in
EGFRvIII and PTEN expression (20). GBM39 cells were
treated with CC214-1 in neurosphere cultures, after which
the EGFR- and EGFRvIII-positive tumor cells were sorted
using cetuximab-conjugated oligonucleotides and captured
on a glass slide arrayed with their complementary oligonu-
cleotide barcodes (Supplementary Fig. S2C). Immunofluo-
rescent stain for PTEN was then conducted (Supplementary
Fig. S2C). Consistently, in this patient-cell model, in which
PTEN is heterogeneously expressed, a shift in the ratio of
PTEN-positive/PTEN-negative cells was observed, with a
significant increase in the percentage of PTEN-positive tumor
cells in response to CC214-1 treatment relative to control.
These data suggest a preferential effect of CC214-1 on the
PTEN-deficient tumors, consistent with our studies in the
isogenic U87-GBM cell lines. Taken together, these data
suggest that EGFRvIII expression and PTEN loss sensitizes
glioblastoma cells to CC214-1–mediated cell-growth arrest.
CC214 potently blocks tumor growth in vivo
We then assessed the potential of CC214-2, an analogue
related to CC214-1 with pharmacokinetic properties suit-
able for in vivo application (10), to inhibit the growth of
U87EGFRvIII cells in vivo (Fig. 3). CC214-2 significantly
reduced the growth of U87EGFRvIII flank xenografts (Fig.
3A) by more than 50%, after 1 week of treatment via oral
gavage. Immunohistochemical analysis showed mTORC1
and mTORC2 inhibition, as measured by diminished P-S6,
P-4E-BP1, and P-Akt cytoplasmic staining (Fig. 3B). CC214-
2 treatment resulted in markedly diminished Ki67 staining
(Fig. 3B). In contrast, no change in terminal deoxynucleo-
tidyl transferase–mediated dUTP nick end labeling
Figure 3. In vivo CC214-2 treatment of U87EGFRvIII ﬂank xenografts
downregulatesmTORC1–mTORC2effector's functions, andsigniﬁcantly
reduces tumor proliferation. A, antitumor activity of CC214-2 in
U87EGFRvIII ﬂank xenograftmodels, after 6 days of oral dosingCC214-2
(50 mg/kg once a day) treatment resulted in greater than 50% tumor
volume reduction. Representative xenografts are shown underneath the
graph. B, immunohistochemistry on U87EGFRvIII xenograft's sections
shows downregulation of the main mTORC1, mTORC2 biomarkers.
TUNEL staining did not change between controls and treated samples,
whereas Ki67, a marker for cell proliferation, was decreased upon
CC214-2 treatment (B). P-S6 (Ser 235-236), P-4E-BP1 (Thr 37-46) denote
mTORC1 effectors, P-Akt (Ser 473) represents mTORC2 activity.
, P < 0.05; , P < 0.01; Student t test; n ¼ 2 and n ¼ 4 respectively for
vehicle and CC214-2–treated ﬂank xenografts; scale bar ¼ 100 mm.
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(TUNEL) staining was detected (Fig. 3B), indicating that
CC214-2–mediated growth inhibition was due to its cyto-
static effect, rather than a consequence of tumor cell death.
CC214-1 and -2 promote autophagy in vitro and in vivo
Inhibition of mTORC1 signaling has been linked to
induction of autophagy, a state in which cells rely on
intracellular degradative machineries to supply biomolec-
ular building blocks to subvert stressful conditions (21).
We hypothesized that induction of autophagy-enabled
U87EGFRvIII glioblastoma cells to resist CC214-1 and
-2–mediated cell death. To test this hypothesis, we exam-
ined the effect of CC214-1 on autophagy induction, and
then determined its functional consequences using genetic
and pharmacologic approaches. We first examined the level
of LC3B-II andAtg5-12, which are recognized as autophagic
biomarkers (Supplementary Fig. S4B). CC214-1 induced
a transient expression of LC3B-II isoform and the conjuga-
tion of Atg12 to Atg5 indicative of the stimulation of the
autophagy flux in U87EGFRvIII cell line (Supplementary
Figure 4. U87EGFRvIII glioblastoma cell line shows higher level of autophagy induction followingCC214-1 exposure. A, time course experimentwithCC214-1
(2 mmol/L) plus the autophagy inhibitor chloroquine (20 mmol/L), in U87EGFRvIII cells, reveals high degree of autophagic ﬂux, registered as accumulation
of LC3B-II, p62 proteins. B, immunoﬂuorescent staining for LC3B protein in U87EGFRvIII cell line. CC214-1 treatment (2 mmol/L) shows typical intra-cellular
autophagosomal puncta pattern (B). C, autophagy induction was registered also in CC214-2 treated (50 mg/kg qd, every day, for 6 days) U87EGFRvIII ﬂank
xenografts as indicated by the higher level of LC3Bmarker, in immunoﬂuorescent staining (top) and immunoblotting (bottom), 24 hours after the last dose as
compared with the vehicle control samples (LC3B staining for the CC214-2 and vehicle treated xenografts respectively in the two top and bottom
photomicrographs; T=CC214-2 treated tumor; C= Vehicle treated tumor). D, time course experiment withCC214-1 (2mmol/L) in U87EGFRvIII cells compared
with U87 cell line shows that EGFRvIII sensitizes cells to CC214-1–mediated induction of autophagy, as shown by themajor increase of LC3B protein and the
higher p62 turnover. Chl., chloroquine. Scale bar: 20 mm.
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Fig. S4B). Further, in the presence of chloroquine, which
inhibits the late stages of autophagy by preventing degra-
dation of autophagosome contents, CC214-1 treatment
led to markedly elevated levels of LC3B-II and p62,
consistent with CC214-1–mediated autophagy (Fig. 4A;
Supplementary Fig. S4C). Immunofluorescence analysis
highlighted enrichment of LC3B with localization into
autophagosomes depicted as puncta (Fig. 4B). In vivo,
CC214-2 similarly activated autophagy in U87EGFRvIII
xenografts (Fig. 4C).
To determine whether EGFRvIII expression sensitized
glioblastoma cells to CC214-mediated autophagy, we com-
pared the level of autophagic flux in three different isogenic
glioblastoma cell lines, with or without EGFRvIII expres-
sion. In U87 glioblastoma cells, or in U373 or LN229
glioblastoma cells in which EGFRvIII expression was under
Figure 5. EGFRvIII-positive cells
from the heterogeneous GBM39
primary neurospheres rely on
autophagy as mechanism to resist
to CC214-1 treatment. Double
immunoﬂuorescent staining for
EGFRvIII (green) and LC3B (red)
on DEAL-captured EGFR wt,
EGFRvIII-positive GBM39 cells
highlights the high level of staining
of the autophagy marker LC3B in
the EGFRvIII-positive cells
(as indicated by the white arrows),
upon CC214-1 (5 mmol/L)
time course treatment
(scale bar ¼ 10 mm).
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the control of a tetracycline-regulated promoter, EGFRvIII
enhanced autophagic flux in response to CC214-1 treat-
ment (Fig. 4D; Supplementary Fig. S5).
To further understand the role of endogenous EGFRvIII
expression in promoting autophagic flux in response to
mTOR kinase inhibition in glioblastoma, we used DEAL
technology (19) to capture and analyze individual EGFR-
vIII-expressing tumor cells from the heterogeneous patient-
derived glioblastoma model, GBM39 (20). GBM39 cells
were treatedwithCC214-1 and theEGFR, EGFRvIII-positive
tumor cells were captured by DEAL as previously described
(Fig. 5). The captured glioblastoma cells were stained using
double immunofluorescence for EGFRvIII and LC3B pro-
teins (Fig. 5). The DEAL captured EGFRvIII-positive cell
were highly positive for punctate LC3B immunostaining
upon CC214-1 treatment (Fig. 5). Western blot analysis
confirmed the induction of autophagy in GBM39 cells,
characterized by massive lipidation of LC3B-I to LC3B-II
isoform (Supplementary Fig. S6A).
These results raised the possibility that EGFRvIII, while
sensitizing glioblastoma cells to mTOR kinase growth inhi-
bition, may also protect them from cell death by engaging
autophagy. High levels of autophagy have been previously
described in oncogene-addicted tumormodels, with activat-
ing mutations in Ras (22), and in glioblastoma cells treated
withPI3K/mTORkinase inhibitors (23). In fact, inductionof
autophagy has been shown to protect glioblastoma cells
from PI3K/mTOR-kinase-inhibitor–induced tumor cell
death in a chloroquine-reversible fashion (23). Therefore,
we set out to use genetic and pharmacologic approaches to
determine whether inhibition of autophagy could sensitize
glioblastoma cells to CC214-1–dependent cell death. Chlo-
roquine abrogated CC214-1–mediated autophagy, signifi-
cantly sensitizing glioblastoma cells to CC214-1–dependent
Figure 6. In vivo combinatory treatment in U87EGFRvIII orthotopic xenografts with CC214-2 and chloroquine signiﬁcantly reduced tumor growth and induced
tumor cell death. A, ﬂuorescence molecular tomography (FMT) images showing the antitumor activity of CC214-2 in single treatment or in combination
with chloroquine in U87EGFRvIII intracranial xenograft models, after 6 days of dosing. B, CC214-2 treatment resulted in greater than 50% reduction
of tumor volume as assessed by FMT imaging. C, CC214-2 treatment signiﬁcantly inhibited mTORC1 and mTORC2 signaling, and reduced the Ki67
proliferation index. C, chloroquine treatment suppressed autophagy, as measured by enhanced p62 staining, promoting tumor cell death (TUNEL-positive
staining) of CC214-2–treated mice. , P < 0.05; , P < 0.01; Student t test (n ¼ 8 for the orthotopic xenografts; CC214-2, 100 mg/kg, once every 2 days by
gavage; chloroquine, 30 mg/kg, once every 2 days intraperitoneally; Ve, vehicle; CC, CC214-2; Chl., chloroquine).
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cell death, particularly in EGFRvIII-expressing tumor cells
(Supplementary Fig. S7A and S7B). Consistent with this
model, genetic inhibition of autophagy achieved through
ATG5 knockdown similarly sensitized glioblastoma cells to
massive tumor cell death in response to CC214-1 (Supple-
mentary Fig. S6B–S6D).
In an intracranial glioblastoma model, CC214-2
inhibits mTORC1 and mTORC2 signaling and
suppresses tumor growth, and additionof chloroquine
promotes tumor cell death
Finally, to assess the potential efficacy of mTOR kinase
inhibition in an intracranial glioblastoma model, and to
assess the relative benefit of combining pharmacologic
inhibition of autophagy, we developed U87EGFRvIII intra-
cranial xenografts in which the tumor cells were labeled
with the far-red protein TurboFP635 to enable noninvasive
FMT imaging (14). We then assessed the effect of mTOR
kinase inhibition with CC214-2 (100 mg/kg once every 2
days by oral gavage for 6 days) on mTOR pathway inhibi-
tion and tumor growth, and we examined the effect of the
autophagy inhibitor chloroquine (30 mg/kg once every 2
days by intraperitoneal injection), alone or in combination.
CC214-2 treatment resulted in highly significant inhibition
of intracranial glioblastoma growth, concomitant with sig-
nificant inhibition ofmTORC1 andmTORC2 signaling (P <
0.05), and significant inhibition of the Ki67 proliferation
index (P < 0.05; Fig. 6A–C; Supplementary Fig. S7C).
Chloroquine treatment had no effect on mTOR pathway
inhibition or tumor growth as measured by FMT index
(Fig. 6A–C), but did reduce the Ki67 index and elevated
p62 staining (P < 0.05). Importantly, combined treatment
with CC214-2 and chloroquine did not alter tumor mTOR
pathway inhibition or additionally decrease tumor growth
relative to CC214-2 alone; however, it did enhance p62
staining (P < 0.01), and significantly increased TUNEL
staining (P < 0.05; Fig. 6; Supplementary Fig. S7C). Taken
together, these results show thatCC214-2 inhibitsmTORC1
and mTORC2 signaling in an intracranial glioblastoma
model, and suggests that inhibition of autophagy promotes
cell death in response to CC214-2 treatment.
Discussion
mTOR is a critical nexus in tumor cells, linking growth
factor receptor signaling through the PI3K–Akt signaling
pathway, with protein translation, cellular metabolism,
and nutrient and energy status (4, 24). However, the
allosteric mTOR inhibitor rapamycin has failed in the
clinic for patients with glioblastoma, potentially as a
consequence of persistent mTORC2 signaling (6) and
because of the inability of rapamycin to durably suppress
4E-BP1 phosphorylation (8, 25). The findings presented
here suggest that ATP-competitive mTOR kinase inhibi-
tors such as CC214-1 and CC214-2 may be more effective
than rapamycin because of their ability to suppress
mTORC2 signaling and mTORC1-dependent 4E-BP1
phosphorylation.
Currently, the molecular determinants of mTOR kinase
inhibitors are not well understood. Our data show that
EGFRvIII, and to a lesser extent wild-type signaling through
EGFR, enhance the sensitivity to mTOR kinase inhibitors,
whereas the presence of PTEN diminishes that requirement.
This finding occurs in the absence of evidence that CC214
compounds are more effective at blocking mTORC1/2 sig-
naling in the context of EGFR–PI3K pathway activation. On
the contrary, these findings suggest that molecular context
exerts significant effects on the dependence of tumor cells on
mTOR signaling, such that EGFR and PTEN status could
potentially beused to stratify patients for treatment.Notably,
these data indicate that PI3K pathway activation may be the
point of convergence, suggesting that other PI3K activating
lesions in glioblastoma may be critical determinants of
response to ATP-competitive mTOR kinase inhibitors.
Furthermore, these results highlight the importance of
autophagy as a targeted therapy resistance mechanism in
cancer. Our findings are consistent with the work of the
Weiss group, showing that PI3K/mTOR kinase inhibition
induces autophagy in glioblastoma cells (23). Similarly, our
evidences, using genetic and pharmacologic autophagy
inhibition, indicate that blocking autophagy could poten-
tially transform mTOR kinase inhibitors into much more
successful anticancer agents by converting a cytostatic to a
cytotoxic response.
Lastly, the introduction of the DEAL technology to mon-
itor autophagy in single cancer cells, captured from hetero-
geneous patient-derived tumors, clearly shows that endog-
enous EGFRvIII is an active promoter of autophagy in
mTOR-kinase–inhibited tumors.
Autophagy in cancer has a context-dependent function,
representing both, a tumor suppressor role in the early stage
of tumor formation, and, conversely, a tumor survival
process in response to perturbations, such as chemotherapy
treatment (26). As shown by Lock and colleagues, onco-
genic Ras-addicted cells have higher level of basal autop-
hagy (27), making the combination of Ras and autophagy
inhibitors a potentially efficacious treatment for this cancer
phenotype (22). Similarly, PTEN-null glioblastoma cells
also exhibit higher basal levels of autophagy and combining
PI3K/mTOR kinase inhibitors with chloroquine causes
massive tumor cell death in that genetic context. Here, we
identify EGFRvIII as a key determinant of mTOR kinase
inhibitor sensitivity in glioblastoma, show that CC214-2
can inhibit mTORC1 and mTORC2 signaling in an intra-
cranial tumor model and we show that chloroquine, or
genetic autophagy inhibition, dramatically sensitizes glio-
blastomas to CC214-mediated tumor cell death, providing
compelling rationale for combination therapy, coupled to a
strategy for stratifying patients most likely to benefit.
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